David Cruikshank is a Partner at ARCH Venture Partners. Mr. Cruikshank focuses on instrumentation, biotechnology, medical diagnostics & devices, semiconductors, nanotechnology, advanced materials, and information technologies. Since joining ARCH in August 2007, he has supported the formation, investment, and growth of a number of companies. Mr. Cruikshank is currently a Director at AgBiome and Encodia and an Observer at Agrivida. In addition, he previously served as a Director at Omniome (acquired by Pacific BioSciences), Boreal Genomics, and Nanosys, and as an Observer at 908 Devices (NASDAQ: MASS), Twist Bioscience (NASDAQ: TWST), Voxel8 (acquired by Kornit Digital), Arbor Biotechnologies, Ultivue, Cytrellis Biosystems, Genturi, PixelEXX Systems, Ciespace (acquired by ESI), and Crystal IS (acquired by Asahi Kasei).
Mr. Cruikshank was formerly with Toshiba America Electronic Components as a Business Development Manager and was responsible for North American audio, video, and automotive semiconductor product lines with annual sales of $50 million. Prior to that, he was with Conexant Systems as an Industrial Engineer.
Mr. Cruikshank holds an M.B.A. with Honors from the University of Chicago, an M.S. in Industrial Engineering and Operations Research from the University of California, Berkeley, and a B.S. in Mechanical Engineering from the University of California, Los Angeles, where he graduated Summa Cum Laude and was elected to Phi Beta Kappa.